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risk group deﬁnitions lead to heterogeneity in CR rates. Only a small number of studies 
will provide valid estimates of the CR rates in patients with primary AML aged 16–60 
years. However, this restriction may reduce the reliability of the estimates, because 
the estimates will be based on fewer patients. This will thereby increase the uncertainty 
around the ICER of new methods.
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A RETROSPECTIVE CHART REVIEW OF THE TREATMENT OF 
PHENYLKETONURIA IN THE UK AND ASSOCIATED CLINICAL AND 
HEALTH OUTCOMES
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OBJECTIVES: To determine the proportion of phenylketonuria (PKU) patients 
managed successfully using current treatment strategies and to highlight a particular 
group(s) of PKU patients who may be uncontrolled by current treatment. METHODS: 
This is a non-interventional, retrospective, observational study. To date 4 UK sites 
have enrolled into the chart review. Information on patients with PKU or tetrahydro-
biopterin (BH4) deﬁciency was collected over a ﬁve year period (2004–2008). Data 
was collated on demographics, diagnosis, number of uncontrolled episodes, interven-
tions made during an uncontrolled episode and the length of time phenylalanine (Phe) 
levels were above the target level. An uncontrolled episode is deﬁned as three or more 
consecutive Phe levels above the National Society for Phenylketonuria (NSPKU) guide-
line. Interventions can include dietary advice, health care professional phone calls, 
clinic visits, counselling/psychological support, addition or change in use of supple-
ments, social care visits, and hospital admission. Data was analysed to explore the 
treatment of PKU in practice, the accompanying Phe levels and other health and clini-
cal outcomes. RESULTS: Recruitment is being completed. This information will be 
reported as a full dataset in the poster. Thus far data has been collected for 102 
patients across 3 centres (50% male). The age range of patients reviewed was 6–60 
years. A total of 93% of patients had a diagnosis of PKU, 0% BH4 deﬁciency and 
7% unknown. The average number of uncontrolled episodes per patient per year was 
1. An average of 7 interventions were made during each episode. The average length 
of the episode was 176 days. CONCLUSIONS: There is lack of published data on the 
management of PKU in clinical practice. This study provides an analysis of current 
treatment of PKU in clinical practice and its effectiveness on clinical and health out-
comes. The majority of PKU patients within this study had well-controlled Phe levels, 
however a number may beneﬁt from additional treatment.
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EFFECT OF MODERATE-INTENSITY EXERCISE TRAINING AND DIET ON 
BODY COMPOSITION AND EXERCISE CAPACITY IN OBESE CHILDREN
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OBJECTIVES: Childhood obesity is a serious health problem favouring the early 
development of insulin resistance, type-2 diabetes mellitus and cardiovascular diseases. 
Our aim was to investigate multidisciplinary weight-control program applying exercise 
training at maximal fat oxidation (FATmax) zone and diet in three different duration 
on body composition and physical ﬁtness of overweight children. METHODS: Thirty 
overweight pupils (BMI  percentile 90%) of three different elementary schools (age: 
11.7 / 1.9) was included. Body composition was determined by bioelectric imped-
ance method. Graded exercise test (Jaeger Oxycon Pro) was used to determine whole-
body peak fat oxidation by indirect calorimeter. Training heart rate interval was 
determined by as / 10% of FATmax. Physical exercises were prescribed by the 
physiotherapist. Exercise training was performed 2 times /week in the school using 
heart rate monitor under the control of the games master. The training periods were 
56, 101 and 146 days. Dietary proposal was given for the parents of children by the 
dietetics. RESULTS: At the end of the weight-control program percentage of fat mass 
decreased (35.7 / 4.5 vs. 33.0 / 5.5%; p  0.001), muscle mass increased (22.8 
/ 4.6 vs. 24.4 / 5.2 kg; p  0.001). VO2max increased at the longest training 
period only (1841 / 620 vs. 2011 / 642 ml; p  0.043). CONCLUSIONS: Moder-
ate intensity exercise training and diet resulted in favourable changes in the body 
composition in a short term whereas the signiﬁcant improvement of VO2max was 
started only after 5 months training period.
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OBJECTIVES: To assess the impact of measures undertaken to improve data capture 
in the Fabry Outcome Survey (FOS). A physician-directed, multinational database 
established in 2001, FOS aims to advance the understanding and management 
of Fabry disease, a rare lysosomal storage disorder caused by deﬁciency of alfa-
 galactosidase A. METHODS: This initiative, supported by Shire HGT is driven by 
physicians in the management of Fabry disease. In 2006, additional measures were 
introduced to enhance the robustness of data capture: 1) a core dataset was developed 
for assessing disease progression and therapy response; 2) focus was directed at those 
participating centers with q20 patients enrolled in FOS; and 3) research associates 
were employed to monitor data capture and quality. Random samples (25%) of all 
enrolled patients were selected from the years 2004 and 2007, before and after the 
changes, respectively. The completeness of data capture was determined for 10 core 
variables in each year. RESULTS: Data capture was analyzed for 197 of the 815 
patients enrolled in FOS in 2004 and for 404 of the 1616 patients enrolled in 2007. 
Increases in data capture occurred for 9 of 10 core variables; the exception was patient 
weights, which were unchanged at 90% for both years. For key variables, the increases 
were: signs and symptoms, from 66% to 83%; serum creatinine, from 89% to 91%; 
left ventricular mass, from 48% to 55%; NHYA score, from 84% to 87%. In addition, 
the proportion of females enrolled increased from 48% to 54%. CONCLUSIONS: 
Focused efforts on improving data completeness and quality in FOS have been 
 successful, optimizing the value of the database. Regular, accurate data collection 
and audit will increase the quality of FOS data and lead to an improved understanding 
of the management of Fabry disease.
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TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK 
PAIN: RESULTS OF EUROQOL-5 DIMENSION (EQ-5D) AND SHORT 
FORM-36 (SF-36) HEALTH STATUS QUESTIONNAIRES
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OBJECTIVES: To evaluate the efﬁcacy and safety of tapentadol ER in patients with 
moderate-to-severe chronic low back pain. Health status was evaluated using SF-36 
and EQ-5D questionnaires. METHODS: Patients received controlled, adjustable 
twice-daily doses of tapentadol ER (100–250 mg), oxycodone HCl controlled release 
(CR; 20–50 mg), or placebo over a 12-week maintenance period, preceded by a 3-
week titration period. Patients completed the EQ-5D and SF-36 at baseline and at 
speciﬁed visits. EQ-5D evaluates mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression; SF-36 evaluates physical functioning, role-physical, bodily 
pain, general health, vitality, social functioning, role-emotional, and mental health 
dimensions. RESULTS: Of 981 patients randomized, 958 were evaluated for efﬁcacy. 
Compared with placebo, improvements from baseline to endpoint in the SF-36 physi-
cal component summary score were signiﬁcantly greater with tapentadol ER (least-
squares mean difference vs placebo [95% CI], 2.3[1.02,3.58], P  0.001) and 
oxycodone CR (2.3[1.02,3.56], P  0.001). Both active treatment groups were associ-
ated with signiﬁcant improvements over placebo in role-physical (tapentadol ER, 
9.9[4.21,15.49]; oxycodone CR, 9.4[3.83,15.05]; both P  0.001) and bodily pain 
(tapentadol ER, 5.5[2.44,8.55]; oxycodone CR, 6.3[3.23,9.29]; both P  0.001). 
Additionally, tapentadol ER was associated with signiﬁcantly better outcomes versus 
placebo in physical functioning (4.1[0.85,7.33], P  0.013) and vitality (3.2[0.41,6.01], 
P  0.025), while oxycodone CR was not signiﬁcantly different from placebo on these 
parameters (physical functioning, 2.6[−0.66,5.77], P  0.119; vitality, 0.8[−1.99,3.58], 
P  0.576). For both active treatment groups, changes from baseline in general health, 
social functioning, role-emotional, mental health, and mental health summary score 
did not differ signiﬁcantly from placebo (all P  0.285). Compared with placebo, the 
EQ-5D health status index at endpoint improved signiﬁcantly compared with baseline 
with tapentadol ER (0.05[0.01,0.09], P  0.020) and oxycodone CR (0.05[0.01,0.09], 
P  0.019). Incidences of treatment-emergent adverse events were placebo, 59.6%; 
tapentadol ER, 75.5%; and oxycodone CR, 84.8%. CONCLUSIONS: Tapentadol ER 
(100–250 mg bid) signiﬁcantly improved physical and overall health status in patients 
with moderate-to-severe chronic low back pain.
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OBJECTIVES: To examine predictors of adherence to duloxetine therapy and assess 
the association between adherence and health care costs among working-age patients 
with ﬁbromyalgia. METHODS: This study analyzed medical and pharmacy records 
for commercially-insured patients aged 18–64 diagnosed with ﬁbromyalgia who initi-
ated duloxetine between January 1, 2006 and December 31, 2006. The date of ﬁrst 
duloxetine prescription ﬁlled was deﬁned as the index date. Initiation of treatment 
was deﬁned as no pill coverage for duloxetine over the prior 90 days. All patients 
included had at least 30 days supply of duloxetine in the 12 months post-index period. 
Patients with diabetes peripheral neuropathic pain or depression in the 12 months 
pre-index period were excluded. Two study cohorts were constructed based on adher-
ence level to duloxetine (high adherence  medication possession ratio of  0.8). Pre-
dictors of high adherence were examined via logistic regression. Multivariate regression 
models were performed to examine the association between adherence and health care 
costs, controlling for demographics, clinical characteristics, and prior health care costs. 
RESULTS: A total of 4869 ﬁbromyalgia patients were identiﬁed, with a mean age of 
50 years and 88% female. Approximately 68% of duloxetine patients had low adher-
ence over the 12 months follow-up period. Higher average daily dose was associated 
with high adherence (reference group  30 mg; Odds Ratio  3.03, 2.40, and 3.74 for 
31–59 mg, 60 mg, and  60 mg, respectively; all p  0.05). Controlling for differences 
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in demographics and clinical characteristics, patients with high adherence had signiﬁ-
cantly lower total health care costs ($938, p  0.05), primarily due to lower inpatient 
($2,057, p  0.05) and outpatient ($951, p  0.05) costs than patients with low 
adherence. CONCLUSIONS: Higher average daily dose of duloxetine appeared to be 
predictor of high adherence among ﬁbromyalgia patients. High adherence to the 
duloxetine therapy was associated with lower total health care costs.
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TREATING FIBROMYALGIA WITH DULOXETINE: WHAT IS THE 
ASSOCIATION BETWEEN AVERAGE DAILY DOSE, MEDICATION 
ADHERENCE, AND HEALTH CARE COSTS?
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OBJECTIVES: To examine the relationship between average daily dose (ADD) of 
duloxetine, medication adherence, and health care costs among ﬁbromyalgia patients. 
METHODS: This study employed a retrospective cohort design to analyze administra-
tive claims database for commercially-insured patients diagnosed with ﬁbromyalgia 
who initiated duloxetine in 2006, with initiation deﬁned as 90-day medication gap. 
The dispense date of the ﬁrst duloxetine prescription ﬁlled was deﬁned as the index 
date. All patients selected were required to have at least 30 days of duloxetine supply 
in the 12 months follow-up period, and those with diabetic peripheral neuropathic 
pain or depression diagnosis during the prior 12 months were excluded. Five cohorts 
were constructed based on ADD: 30 mg, 30 mg, 31–59 mg, 60 mg, and 60 mg. 
Adherence was measured via medication possession ratio (MPR) of duloxetine over 
12-month post-index period, with MPR  0.8 as high adherence. Multivariate regres-
sion models adjusting for differences in demographic and clinical characteristics were 
used to examine the association between ADD, adherence and health care costs. 
RESULTS: The study sample included 4,869 ﬁbromyalgia patients. Three percent of 
patients had an ADD of 30 mg, 12% of 30 mg, 21% of 31–59 mg, 46% of 60 mg, 
and 18% of 60 mg. Approximately one-third of patients had high adherence. Con-
trolling for demographics and clinical characteristics, patients with ADD  30 mg 
(31–59 mg, and 60 mg) were less (more) likely to adhere to duloxetine than those 
with 60 mg (all p  0.05). Compared with patients maintaining an ADD of 60 mg, 
those with ADD of 31–59 mg or 60 mg had signiﬁcantly higher total health care 
costs ($1835 and $5490, respectively, both p  0.05), while those with an ADD of 
30 mg had signiﬁcantly lower costs ($1853, p  0.05). CONCLUSIONS: Fibromy-
algia patients with an ADD  30 mg of duloxetine were more likely to adhere to 
therapy. Maintaining an ADD of 30 and 60 mg was associated with reduced total 
health care costs.
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DEFI (DETERMINATION OF EPIDEMIOLOGY OF FIBROMYALGIA) A 
FRENCH PREVALENCE STUDY OF FIBROMYALGIA
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OBJECTIVES: To determine ﬁbromyalgia (FM) prevalence in a french general popula-
tion setting, with a clinical conﬁrmation based on ACR criteria METHODS: This 
cross-sectional survey in a general population setting consisted in two steps: First, a 
telephone screening among 6,000 households using the French validated version of 
London Fibromyalgia Epidemiological Study Screening Questionnaire or LFES-SQ [1], 
then a rheumatologist’s conﬁrmation based on ACR criteria [2]. RESULTS: Of 3081 
polled subjects, 232 (7.5%) were screened positive ; 96 subjects accepted the consulta-
tion (41.4%), 70.8% were females. Mean age was 58.2 CI95 [55.2 ; 61.2] years. 
Finally 20 subjects (20.8%) met the ACR criteria, 17 were females. Mean age was 
56.9 CI95 [50.7 ; 63.1]. Thus FM prevalence is estimated to 1.5 % CI 95 [1.1; 2.0] 
based on the following algorithm : Prevalence (%)  [Ndiagnosis  (Ndiagnosis/Nconsultations 
 
Nrefusals)] 
 100/Nscreened patients NRefusals : screened positive patients who refused to 
consult, Ndiagnosis : conﬁrmed FM patients CONCLUSIONS: This 1.5% FM preva-
lence is consistent with other studies but lower than London Fibromyalgia Epidemio-
logical Study ﬁgures (2.7%)[1]. Those discrepancies can be attributable to patient’s 
easier access to specialists and a stricter physician’s interpretation of ACR criteria. [1] 
White KP. J Rheumatol 1999;26:1570–76; [2] Wolfe W. Arthritis & Rheumatism 
1990;33:160–72.
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ECONOMIC AND CLINICAL EFFICACY BENEFITS OF THE USE OF 
USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE 
PSORIASIS IN GREECE
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OBJECTIVES: To estimate the annual and per-patient budget impact of the treatment 
of moderate to severe psoriasis in Greece before and after the introduction of 
ustekinumab. METHODS: A budget impact model was constructed from a National 
Health System perspective to depict the clinical and economic aspects of psoriasis 
treatment in a time frame of ﬁve years. It included drug acquisition, monitoring 
and administration costs for both the induction and maintenance years for patients 
treated with etanercept, adalimumab, inﬂiximab, with or without ustekinumab. It also 
considered the resource utilisation for non-responders. Greek treatment patterns and 
resource utilization data were derived from 110 interviews with dermatologists and 
an expert panel of 18 key opinion leaders of dermatology. Ofﬁcial published sources 
were used to derive the unit costs. Costs of adverse events and indirect costs were 
excluded from the analysis. The treatment response was deﬁned as probability of 
achieving a PASI 50, PASI 75 or PASI 90 response, based on published clinical trial 
data. RESULTS: The inclusion of ustekinumab in the biological treatment mix for 
moderate to severe psoriasis can lead to total per-patient savings of a481 and a1027 
in the ﬁrst and ﬁfth year of its introduction, respectively. The annual savings just on 
the hospitalisation costs of non-responders were estimated to be a900,000 in the ﬁrst 
year and a3 million in the ﬁfth. The cost savings were attributed to the reduced 
administration costs, reduced hospitalisations for non-responders, and improved efﬁ-
cacy. In an induction year and maintenance year (2-year period), there are a total of 
9 administrations for ustekinumab compared to 116 for etanercept, 54 for adalim-
umab and 15 for inﬂiximab. CONCLUSIONS: The inclusion of ustekinumab in the 
treatment of moderate to severe psoriasis in Greece is anticipated to have both short- 
and long-term health and economic beneﬁts both on an annual and per-patient 
basis.
PSY13
REIMBURSEMENT OF FOODS FOR SPECIAL MEDICAL PURPOSES 
PRODUCTS FOR PHENYLKETONURIA IN POLAND: A BUDGET IMPACT 
ANALYSIS
Rys P, Marcisz A, Palka I, Plisko R, Wladysiuk M
HTA Consulting, Krakow, Poland
OBJECTIVES: The aim of the analysis was to estimate the budget impact of including 
new foods for special medical purposes (FSMP) for phenylketonutria (PKU) on the 
reimbursement list in Poland. Patients with phenylketonuria must adhere to phenyl-
alanine-restricted diet in order to prevent neurological impairment. METHODS: In 
2008 the reimbursement list in Poland included several FSMP; however, most of them 
were relatively old (basic portfolio). On the other hand, there were a lot of new PKU 
products not yet reimbursed (milupa pku2 prima, milupa pku2 secunda, milupa pku2 
shake, milupa pku3 advanta, milupa pku3 shake, milupa pku3 tablets, Minaphlex, 
Lophlex, Easiphen, XP_Maxamum). This analysis was performed from the public 
payer’s perspective (National Health Fund). A 5-year time horizon was adopted 
(2009–2013). The prognosis was based on the assumption that the PKU products sales 
in Poland will increase at the same rate as in the past few years. The market shares 
of speciﬁc PKU products were estimated based on data obtained from other European 
countries (scenario 1) and a questionnaire survey (scenario 2). The base scenario, 
assuming no changes on the reimbursement list, was also deﬁned. Total and incre-
mental costs were calculated. Incremental costs were deﬁned as the difference between 
scenario 1 (or scenario 2) and the base scenario. RESULTS: In the base scenario the 
total cost related to reimbursement of PKU products would amount to 23.95 million 
PLN in 2009 and 25.82 million PLN in 2013. In scenario 1, the expenditure for PKU 
products would increase by 0.3 million PLN in 2009 and 1.4 million PLN in 2013. 
In scenario 2 the expenditure would increase by 0.9 million PLN in 2009 and 2.9 
million PLN in 2013. CONCLUSIONS: This analysis showed that reimbursement of 
new PKU products would be associated with an incremental cost of about 3 million 
PLN.
PSY14
COST-EFFECTIVENESS AND BUDGET IMPACT OF LOW DOSE 7-DAY 
BUPRENORPHINE PATCH FOR MODERATE TO SEVERE 
OSTEOARTHRITIS PAIN IN THE CONTEXT OF KOREA NATIONAL 
HEALTH INSURANCE
Lim EA, Park JA, An YJ, Goo DH, Choi SE
Seoul National University, Seoul, South Korea
OBJECTIVES: Low dose 7-day buprenorphine transdermal patch (norspan®) is an 
opioid analgesic indicated in the management of chronic moderate to severe pain not 
responding to non-opioid analgesics. This patch has been marketed as products not 
covered by the national health insurance. The purpose of this analysis was to evaluate 
cost-effectiveness and budget impact of the buprenorphine patch, thereby assessing its 
eligibility for National Health Insurance coverage. METHODS: We carried out a 
cost-effectiveness analysis of the buprenorphine patches compared to tramadol tablets 
in patients with chronic, moderate to severe osteoarthritis (OA) pain, using a third-
party-payers perspective. The time horizon of analysis was 12-week. During this 
period, it was assumed that doses of study medication were titrated twice to achieve 
stable pain control. Patients’ global impression of pain relief was used as a clinical 
outcome variable, based on which we deﬁned good and very good pain relief as con-
trolled pain. Expert survey was conducted to investigate the treatment pattern and the 
cost of chronic pain. Budget impact analysis was applied to assess the impact of insur-
ance coverage of buprenorphine patches. Sensitivity analysis was performed for major 
parameters and possible scenarios. RESULTS: Buprenorphine patch was dominant 
compared to its comparator, displaying increased effectiveness and reduced costs. 
Budget impact analysis for 5 years indicated drug costs might increase by nearly 12.2 
billion won upon application of buprenorphine patch for insurance coverage; however, 
the budget for National Health Insurance including medical cost might decrease by 
nearly 2.9 billion won mainly due to decrement dispensing fee. Sensitive analysis sug-
gested that the most sensitive variable was the effectiveness of buprenorphine patches. 
CONCLUSIONS: Low dose 7-day buprenorphine patch was a cost-effective and cost-
saving alternative in the Korea National Health Insurance context. Study robustness 
needed more evidences about effectiveness.
